Central Nervous System Adverse Reactions to Amantadine Intoxication: A Case Report and Analysis of JADER.
Autor: | Ide N; Department of Practical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan; n-ide@nichiyaku.ac.jp., Hosoya Y; Department of Practical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan., Yamamoto M; Department of Pharmacy, Chutoen General Medical Center, Shizuoka, Japan., Shigeno A; Department of Trauma, Critical Care Medicine and Burn Center, Japan Community Health Care Organization Chukyo Hospital, Aichi, Japan., Obayashi M; Department of Emergency and Critical Care Medicine, Chutoen General Medical Center, Shizuoka, Japan., Asada K; Department of Emergency and Critical Care Medicine, Chutoen General Medical Center, Shizuoka, Japan., Matsushima S; Department of Emergency and Critical Care Medicine, Chutoen General Medical Center, Shizuoka, Japan. |
---|---|
Jazyk: | angličtina |
Zdroj: | In vivo (Athens, Greece) [In Vivo] 2024 Jul-Aug; Vol. 38 (4), pp. 2090-2096. |
DOI: | 10.21873/invivo.13669 |
Abstrakt: | Background/aim: A few case reports of central nervous system (CNS) symptoms caused by amantadine intoxication have been published, detailing various types of symptoms and differing times to onset. We encountered a patient who developed CNS symptoms with amantadine. This prompted us to investigate the types, time to onset, and outcome of CNS adverse reactions to amantadine by analyzing data from a pharmacovigilance database. Patients and Methods: The patient was evaluated at Chutoen General Hospital, Shizuoka, Japan. Analysis was performed using the Japanese Adverse Drug Event Report (JADER) database. Results: In our case, the amantadine blood concentration was 4,042 ng/ml, i.e., in the toxic range. The time to onset was 26 days for dyskinesia and 90 days for depressed level of consciousness. Symptoms resolved when amantadine was discontinued. The JADER database contained 974 cases of adverse reactions to amantadine. The most frequently reported CNS adverse reaction was hallucination, with a reporting odds ratio of 64.28 (95% confidence interval=52.67-78.46). Positive signals were detected for all CNS adverse reactions. For all CNS reactions, clinical outcomes were poor in a comparatively low percentage of cases. Most CNS reactions occurred soon after administration of amantadine, usually within approximately one month. Conclusion: Because most CNS adverse reactions to amantadine usually occur within approximately one month of initiating treatment, healthcare providers should exercise heightened vigilance in monitoring patients for such reactions during this period. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |